The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
An article from
Startup launches
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
Published June 10, 2026
A light beam shines through the retina and lens on an eye exam.
Ethyreal lands $101M to treat both Graves' and thyroid eye disease
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, others - The Economic Times
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
City Therapeutics gets $99M to gather data on three RNAi medicines
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Alterity
Kiran Mazumdar-Shaw founded Immuneel Therapeutics raises Rs 100 crore in Series B Funding
Enliven Therapeutics' leukemia drug shows promise in new study
Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye…
Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might…
It'll be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
The Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out,…
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA…
